MARKET

NBSE

NBSE

Neubase Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8500
-0.0400
-4.49%
After Hours: 0.8100 -0.04 -4.71% 16:52 06/24 EDT
OPEN
0.9100
PREV CLOSE
0.8900
HIGH
0.9489
LOW
0.7900
VOLUME
63.51K
TURNOVER
0
52 WEEK HIGH
5.45
52 WEEK LOW
0.7900
MARKET CAP
27.42M
P/E (TTM)
-0.8125
1D
5D
1M
3M
1Y
5Y
NeuBase to Participate at the Jefferies Healthcare Conference
PITTSBURGH and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of preci...
GlobeNewswire · 06/01 11:00
--HC Wainwright Adjusts NeuBase Therapeutics' Price Target to $10 From $15, Keeps Buy Rating
MT Newswires · 05/31 08:15
NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution
PITTSBURGH and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precis...
GlobeNewswire · 05/17 11:00
--Chardan Capital Adjusts NeuBase Therapeutics' Price Target to $9 from $18, Keeps Buy Rating
MT Newswires · 05/13 10:57
BRIEF-NeuBase Therapeutics Reports Results For The Second Quarter Of Fiscal Year 2022
reuters.com · 05/12 21:22
NeuBase Therapeutics GAAP EPS of -$0.30 misses by $0.06
NeuBase Therapeutics press release (NASDAQ:NBSE): Q2 GAAP EPS of -$0.30 misses by $0.06. With continued positive results from in vitro and in vivo preclinical studies, the Company expects to file an IND application for
Seekingalpha · 05/12 21:09
Insiders who bought in the last 12 months lose an additional US$65k as NeuBase Therapeutics, Inc. (NASDAQ:NBSE) drops to US$29m
Insiders who bought US$108k worth of NeuBase Therapeutics, Inc.'s ( NASDAQ:NBSE ) stock at an average buy price of...
Simply Wall St. · 05/12 14:53
NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
PITTSBURGH and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precis...
GlobeNewswire · 05/02 20:30
More
No Data
Learn about the latest financial forecast of NBSE. Analyze the recent business situations of Neubase Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NBSE stock price target is 12.00 with a high estimate of 17.00 and a low estimate of 9.00.
High17.00
Average12.00
Low9.00
Current 0.8500
EPS
Actual
Estimate
-0.24-0.18-0.12-0.06
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 62
Institutional Holdings: 12.40M
% Owned: 38.45%
Shares Outstanding: 32.26M
TypeInstitutionsShares
Increased
8
473.55K
New
6
1.10M
Decreased
12
375.09K
Sold Out
7
61.03K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Chairman/President/Chief Executive Officer/Director
Dietrich Stephan
Chief Financial Officer
Todd Branning
Chief Operating Officer
William Mann
Other
Sandra Rojas-Caro
Director
Eric Ende
Independent Director
Dov Goldstein
Independent Director
Gerald McDougall
Independent Director
Franklyn Prendergast
Independent Director
Eric Richman
No Data
No Data
About NBSE
NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.

Webull offers kinds of Neubase Therapeutics Inc stock information, including NASDAQ:NBSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBSE stock methods without spending real money on the virtual paper trading platform.